• Home
  • Contact Us!
  • Privacy Policy

Radio Metta

  • Home
  • Business
  • Education
  • Health
  • Home Deco
  • News
  • Real Estate
  • Technology
  • Contact Us!
  • Privacy Policy
Home» Health»FDA approves biosimilar to Remicade for arthritis, IBS

FDA approves biosimilar to Remicade for arthritis, IBS

Saheli 07 Apr 2016 Health Comments Off on FDA approves biosimilar to Remicade for arthritis, IBS 9 Views

BETHESDA, Md., April 6 — A drug very similar to Remicade was approved by the U.S. Food and Drug Administration for treatment of Crohn’s disease, rheumatoid arthritis, irritable bowel syndrome and other chronic conditions, the agency said.

Inflectra is a biosimilar to Remicade, and while not a direct copy, it matches the original for safety and efficacy, and is expected to offer patients access to an additional treatment method because of its lower cost.

The drug is only the second biosimilar approved by the FDA, a group of drugs grown in living cells that are similar in all clinical effects to the original — similar to generic chemicals in pills mixed in different ways from the drug’s original developer.

Pfizer, which licensed Inflectra for U.S. distribution from the South Korean company Celltrion, said it plans to launch the drug this year. Pfizer said in a press release, however, the timing would be based on “marketplace dynamics and intellectual property considerations,” including a lawsuit filed by Johnson and Johnson, the maker of Remicade, to prevent Inflectra from going on sale.

“Biosimilars can provide access to important treatment options for patients who need them,” said Dr. Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research, in a press release. “Patients and the health care community can be confident that biosimilar products are high quality and meet the agency’s rigorous scientific standards.”

The FDA approved Inflectra as an injectible treatment for moderate to severe Crohn’s disease in adults and children, and adults with ulcerative colitis, rheumatoid arthritis, spinal and psoriatic arthritis and chronic severe plaque psoriasis.

Biosimilars are expected to have an effect similar to generic pills, making drug treatment available to more people who need it. While the Affordable Care Act includes considerations to motivate the development of biosimilars, pharmaceutical companies have already taken action to stop them, with Johnson and Johnson filing suit against Celltrion last year.

Johnson and Johnson claims in the suit that Celltrion is violating six patents the company holds for Remicade, one of which does not expire until 2027, the Wall Street Journal reports. The patent for the drug’s make-up expires in 2018, at which time companies will be able to copy the drug, rather than creating something similar to it.

While the FDA did not designate the drug as interchangeable with Remicade, as Johnson and Johnson points out, the list of conditions it is approved to treat are about the same.

Inflectra was previously approved in 71 other countries, and is likely to help more patients for whom Remicade has been out of reach, its developers in South Korea said.

“As one of the first companies to navigate the biosimilar approval pathway with the FDA, we believe this approval will be an essential step in helping to clarify the application process for these critical medicines,” HyoungKi Kim, chief executive officer of Celltrion, said in a press release. “Our experience with biosimilars outside the U.S. suggests that Inflectra provides patients with both therapeutic and financial benefits, and we hope to see the same value provided in the U.S.”

[Source:- UPI]

approves arthritis biosimilar FDA for IBS Remicade to 2016-04-07
Tags approves arthritis biosimilar FDA for IBS Remicade to
Facebook Twitter Stumble linkedin Pinterest More

Authors

Posted by : Saheli
Previous Article :

Kamla Advani passes away

Next Article :

Single-sex schools ‘must adapt for transgender pupils’

Related Articles

Firefly Health Taps Oshi Health to Add Whole-Person Digestive Care to Its Virtual Specialty Network

Loknath Das 06 Jun 2022

This Relentless Pandemic Can Tax Your Mental Health. Here’s How to Cope

Loknath Das 11 Apr 2022

Study: Two New Early Signs of Parkinson’s Disease Identified

Loknath Das 05 Apr 2022

Latest Post

News

Your SEO Budget Is Determining Your Success

admin 03 Sep 2022
News

WAN Connection Method – Frame Relay

admin 26 Aug 2022
Education

GESS Proudly Supports and Sponsors UAE Based Team in Global STEM Challenge

Loknath Das 28 Jul 2022
Technology

The Samsung Galaxy Z Flip4 gets FCC certification

Loknath Das 22 Jul 2022
Education

USF faculty, students to present at 2022 American Educational Research Association Annual Meeting

Loknath Das 22 Jul 2022
Technology

“Critical” We Understand Digital Money’s Impact: US Policymaker

Loknath Das 07 Jun 2022
Health

Firefly Health Taps Oshi Health to Add Whole-Person Digestive Care to Its Virtual Specialty Network

Loknath Das 06 Jun 2022
June 2023
M T W T F S S
 1234
567891011
12131415161718
19202122232425
2627282930  
« Sep    
  • Home
  • Contact Us!
  • Privacy Policy
Copyright 2016, All Rights Reserved
Magazine Blog News WordPress Theme